← The Wire
XFORNasdaq
X4 Pharmaceuticals, Inc
Biological Products, (No Diagnostic Substances) · DE · CIK 1501697
Develops and commercializes novel therapeutics for rare hematology diseases, including mavorixafor for WHIM syndrome and chronic neutropenia
red 8-K · 90d
$377M
Market cap
$4.23
Last close
+5.2%
1D
+2.7%
5D
592K
Volume
Price · last 39 sessions+0.5%
May 4L $3.64 · H $4.50Jun 29
249
Total filings
May 13, 2026
Last filing
12/31
Fiscal year end
SC 13DGROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / X4 PHARMACEUTICALS, INC. -- SCHEDULE 1Jul 19, 2022SC 13DSC 13DMar 22, 2019SC 13DSCHEDULE 13DDec 6, 2018SC 13DSC 13DFeb 14, 2018SC 13DSCHEDULE 13DNov 30, 2017SC 13DSC 13DNov 29, 2017SC 13DNEW ENTERPRISE ASSOCIATES 16, L.P. - ARSANIS, INC. 13DNov 29, 2017
Insider Activity
In the 90 days to Oct 23, 2025: 1 insider bought $250K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 23, 2025 | Craig Adam RExecutive Chairman | Buy | 86,206 | $2.90 | $250K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance